Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

21.82
+0.56002.63%
Post-market: 22.090.2685+1.23%19:41 EDT
Volume:1.42M
Turnover:31.26M
Market Cap:4.24B
PE:-43.57
High:22.37
Open:21.44
Low:21.38
Close:21.26
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:90.19M
Volume Ratio:0.58
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:3.45
PE(LYR):-13.47

Loading ...

Legend Biotech's Q1 2026 Earnings Preview: CARVYKTI Sales Projected at Approximately $597 Million

Deep News
·
May 11

Earning Preview: Legend Biotech Q1 revenue is expected to increase by 58.58%, and institutional views are bullish

Earnings Agent
·
May 05

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

GlobeNewswire
·
May 04

Is Growing Focus On CAR-T Data And CARVYKTI Orders Reframing Legend Biotech’s (LEGN) Investment Story?

Simply Wall St.
·
May 02

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

GlobeNewswire
·
Apr 28

Legend Biotech Soars Over 40% in 5 Days: Is Lilly's $7B Bet Revealing a Deeply Undervalued Gem?

Stock News
·
Apr 22

Legend Biotech Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 21

Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Arrowhead Pharmaceuticals (ARWR) and Legend Biotech (LEGN)

TIPRANKS
·
Apr 20

Legend Biotech Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 15

BUZZ-Genscript Biotech climbs as cancer drug CARVYKTI generated $597 mln sales

Reuters
·
Apr 15

Legend Biotech Reports Preliminary Q1 2026 CARVYKTI Sales of About $597 Million

TIPRANKS
·
Apr 14

RBC Capital Sticks to Their Buy Rating for Legend Biotech (LEGN)

TIPRANKS
·
Apr 09

Legend Biotech Earnings Call Highlights CARVYKTI Momentum

TIPRANKS
·
Apr 03

Is Legend Biotech (LEGN) Pricing Reflect Its Value After Recent Share Price Rebound?

Simply Wall St.
·
Apr 02

Legend Biotech Corp : Piper Sandler Cuts Target Price to $64 From $78

THOMSON REUTERS
·
Mar 30

Legend Biotech CEO Makes Notable Insider Move in Latest Stock Transaction

TIPRANKS
·
Mar 28

J&J Exits 3 Biotechs, Retains Stakes in 2 Possible Acquisitions -- Barron's

Dow Jones
·
Mar 28

Legend Biotech director Tomas J. Heyman files Form 3 initial beneficial ownership statement

Reuters
·
Mar 19

Legend Biotech files Form 3 as director Meng Robin reports no beneficial ownership securities

Reuters
·
Mar 19

Legend Biotech director Casey Patrick John files initial beneficial ownership statement

Reuters
·
Mar 19